Galectin-3: clinical utility and prognostic value in patients with heart failure
Frank KramerClinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, GermanyAbstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available abo...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-02-01
|
| Series: | Research Reports in Clinical Cardiology |
| Online Access: | http://www.dovepress.com/galectin-3-clinical-utility-and-prognostic-value-in-patients-with-hear-a12144 |
| id |
doaj-ee4733a33de8467298da30ede4c6d696 |
|---|---|
| record_format |
Article |
| spelling |
doaj-ee4733a33de8467298da30ede4c6d6962020-11-25T02:38:51ZengDove Medical PressResearch Reports in Clinical Cardiology1179-84752013-02-012013default1322Galectin-3: clinical utility and prognostic value in patients with heart failureKramer FFrank KramerClinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, GermanyAbstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratificationhttp://www.dovepress.com/galectin-3-clinical-utility-and-prognostic-value-in-patients-with-hear-a12144 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Kramer F |
| spellingShingle |
Kramer F Galectin-3: clinical utility and prognostic value in patients with heart failure Research Reports in Clinical Cardiology |
| author_facet |
Kramer F |
| author_sort |
Kramer F |
| title |
Galectin-3: clinical utility and prognostic value in patients with heart failure |
| title_short |
Galectin-3: clinical utility and prognostic value in patients with heart failure |
| title_full |
Galectin-3: clinical utility and prognostic value in patients with heart failure |
| title_fullStr |
Galectin-3: clinical utility and prognostic value in patients with heart failure |
| title_full_unstemmed |
Galectin-3: clinical utility and prognostic value in patients with heart failure |
| title_sort |
galectin-3: clinical utility and prognostic value in patients with heart failure |
| publisher |
Dove Medical Press |
| series |
Research Reports in Clinical Cardiology |
| issn |
1179-8475 |
| publishDate |
2013-02-01 |
| description |
Frank KramerClinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, GermanyAbstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification |
| url |
http://www.dovepress.com/galectin-3-clinical-utility-and-prognostic-value-in-patients-with-hear-a12144 |
| work_keys_str_mv |
AT kramerf galectin3clinicalutilityandprognosticvalueinpatientswithheartfailure |
| _version_ |
1724789300790296576 |